May 7 (Reuters) - Cytosorbents Corp ::CYTOSORBENTS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES SECOND QUARTER 2019 GUIDANCE.Q1 REVENUE $5.2 MILLION VERSUS REFINITIV IBES ESTIMATE OF $6.2 MILLION.BELIEVE THAT WE HAVE SUFFICIENT CASH TO FUND OUR OPERATIONS INTO 2020.QTRLY LOSS PER SHARE $0.15.CONTINUE TO FORECAST STRONG REVENUE GROWTH FOR ALL OF 2019, DESPITE A SLOW START IN Q1.Q2 2019 PRODUCT SALES ARE EXPECTED TO RETURN TO OUR HISTORICAL GROWTH TRAJECTORY.CYTOSORBENTS - Q2 PRODUCT SALES ANTICIPATED TO BE HIGHEST QUARTERLY PRODUCT SALES REPORTED IN CO'S HISTORY.
Full Article
March 7 (Reuters) - Cytosorbents Corp ::CYTOSORBENTS ACHIEVES RECORD REVENUE AND PRODUCT SALES GROWTH IN 2018.CYTOSORBENTS CORP - EXPECT Q1 2019 PRODUCT SALES TO EXCEED SALES REPORTED IN Q1 OF 2018.
Full Article
March 5 (Reuters) - Cytosorbents Corp ::CYTOSORBENTS - EXPANDED DIRECT SALES OF CYTOSORB FOR ALL APPLICATIONS TO POLAND, NETHERLANDS, & FOR CRITICAL CARE APPLICATIONS IN SWEDEN, DENMARK, NORWAY.CYTOSORBENTS CORP - COMPANY ESTABLISHED CYTOSORBENTS POLAND SP. Z.O.O., A WHOLLY-OWNED SUBSIDIARY OF CYTOSORBENTS EUROPE GMBH.
Full Article
Jan 7 (Reuters) - Cytosorbents Corp ::CYTOSORBENTS ISSUES STOCKHOLDER LETTER WITH PRELIMINARY 2018 FINANCIAL RESULTS.SEES FY 2018 REVENUE AT LEAST $22.3 MILLION.SEES Q4 2018 PRODUCT SALES OF APPROXIMATELY $5.4 MILLION.Q4 REVENUE VIEW $6.3 MILLION -- REFINITIV IBES DATA.FY2018 REVENUE VIEW $22.7 MILLION -- REFINITIV IBES DATA.
Full Article
Aug 21 (Reuters) - Cytosorbents Corp ::CYTOSORBENTS AWARDED UP TO $3M IN SBIR PHASE IIB BRIDGE FUNDING BY NIH/NHLBI.
Full Article
July 26 (Reuters) - Cytosorbents Corp ::CYTOSORBENTS FILES FOR MIXED SHELF OF UP TO $150 MILLION - SEC FILING.
Full Article
Jan 8 (Reuters) - Cytosorbents Corp ::CYTOSORBENTS PRE-ANNOUNCES PRELIMINARY FOURTH QUARTER AND FULL YEAR 2017 RESULTS AND ISSUES STOCKHOLDER LETTER.SEES Q4 2017 REVENUE ABOUT $4.6 MILLION.SEES FY 2017 REVENUE $15 MILLION.- WITH NEW TAX LAW, AND WITH SUBSTANTIAL FEDERAL NET OPERATING LOSSES "WE WILL NOT PAY FEDERAL INCOME TAX FOR A LONG TIME".
Full Article
Dec 21 (Reuters) - Cytosorbents Corp ::CYTOSORBENTS ACHIEVES KEY MILESTONE WITH FDA APPROVAL OF THE U.S. REFRESH 2 PIVOTAL CARDIAC SURGERY TRIAL IDE APPLICATION.U.S. FDA GRANTED APPROVAL OF REFRESH 2 INVESTIGATIONAL DEVICE EXEMPTION APPLICATION, WITH CONDITIONS.CONDITIONS RELATE TO REQUESTED CLARIFICATIONS, CHANGES TO PATIENT CONSENT FORM & INSTRUCTIONS FOR USE DOCUMENT.
Full Article
Nov 9 (Reuters) - Cytosorbents Corp :Cytosorbents continues strong trajectory of growth in the third quarter 2017.Total Q3 2017 revenues increased 59% to $3.8 million.
Full Article
Earnings vs. 
Estimates